Naringenin Protected Against Blood Brain Barrier Breakdown after Ischemic Stroke through GSK-3β/ β-Catenin Pathway

Neurochem Res. 2024 Nov 18;50(1):17. doi: 10.1007/s11064-024-04259-w.

Abstract

Protection against blood-brain barrier (BBB) dysfunction is key to reduce the cerebral ischemia injury as its breakdown causes edema formation and extravasation of blood components and immune cells. The maintenance of BBB integrity requires the GSK-3β/β-catenin pathway activity. Naringenin (NAR), an effective monomer from Chinese herbal medicine, had potent protective effect on brain inflammatory and oxidative injury. However, whether NAR could protect the integrity of BBB during cerebral ischemia injury and the involvement of GSK-3β/β-catenin pathway in the beneficial effect of NAR was unknown. Therefore, mouse middle cerebral artery occlusion/reperfusion (IR) model was employed to answer these questions. NAR was intraperitoneally administrated once daily for 6 days immediately after IR with the dose of 10 mg/kg. BBB damage was evaluated with Evans blue. Protein levels of GSK-3β and β-catenin in vascular endothelial cells at penumbra were assessed with western blotting and immunofluorescence. The experimental data suggested that NAR improved neurological deficits, decreased the percentage of infarct volumes and neuronal apoptosis at 7d after IR. NAR improved BBB damage as evidenced by a lower permeability of Evans blue dye and upregulation of tight junction proteins such as zonula occludens-1(ZO-1), Occludin and Claudin-5. Importantly, GSK-3β/β-catenin pathway activity was related to the improvement of BBB integrity rendered by NAR. Our findings demonstrated that NAR might become a potential therapeutic drug for IR.

Keywords: BBB; GSK-3β; IR; Naringenin; β-catenin.

MeSH terms

  • Animals
  • Blood-Brain Barrier* / drug effects
  • Blood-Brain Barrier* / metabolism
  • Brain Ischemia / drug therapy
  • Brain Ischemia / metabolism
  • Flavanones* / pharmacology
  • Flavanones* / therapeutic use
  • Glycogen Synthase Kinase 3 beta* / metabolism
  • Infarction, Middle Cerebral Artery / drug therapy
  • Infarction, Middle Cerebral Artery / metabolism
  • Infarction, Middle Cerebral Artery / pathology
  • Ischemic Stroke / drug therapy
  • Ischemic Stroke / metabolism
  • Ischemic Stroke / pathology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Neuroprotective Agents* / pharmacology
  • Neuroprotective Agents* / therapeutic use
  • Signal Transduction / drug effects
  • beta Catenin* / metabolism

Substances

  • Flavanones
  • naringenin
  • Glycogen Synthase Kinase 3 beta
  • beta Catenin
  • Neuroprotective Agents
  • CTNNB1 protein, mouse